A Prospective Evaluation of Shortened Course Oral N-Acetylcysteine for the Treatment of Acute Acetaminophen Poisoning
Study objective
Treatment with a shortened duration of oral N-acetylcysteine (20 to 48 hours) after acute acetaminophen poisoning is effective in the prevention of subsequent hepatic failure and death when administered to individuals meeting appropriate laboratory criteria.
Methods
Individuals with a potentially toxic acetaminophen ingestion according to serum acetaminophen levels were identified prospectively using a large statewide poison control system database throughout a 12-month period. N-acetylcysteine was administered for a minimum of 6 doses (20 hours), after which laboratory studies were obtained. Discontinuation of N-acetylcysteine was recommended by the poison center when 2 criteria were met: serum acetaminophen was undetectable (<10 μg/mL) and liver test results were normal (serum aminotransferase, international normalized ratio). A follow-up questionnaire was administered to individuals treated with N-acetylcysteine for 48 hours or less to ascertain the presence of symptoms consistent with progressive hepatotoxicity.
Results
Of 205 acutely poisoned individuals treated with N-acetylcysteine for 48 hours or less, 195 were successfully contacted after discharge, and 187 of 195 (95.9%) reported no symptoms consistent with hepatic failure. Eight individuals (4.1%) reported abdominal pain or vomiting; however, none received further N-acetylcysteine treatment or additional hospitalization.
Conclusion
A shortened duration of treatment with N-acetylcysteine (20 to 48 hours) may be an effective treatment option in individuals considered to be at no further risk of developing liver toxicity according to the fulfillment of appropriate laboratory criteria before N-acetylcysteine discontinuation.
To access this article, please choose from the options below
Supervising editor: Richard C. Dart, MD, PhDAuthor contributions: DPB was principal investigator. DPB, FLC, SRW, and RFC conceived and designed the study. DPB, SCT, and RFC identified eligible study participants and collected and recorded all data. SRW and RFC supervised data collection and analysis. DPB drafted the article, and FLC, SRW, and RFC contributed substantially to its revisions. DPB is responsible for the paper as a whole.Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that may create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.Available online March 30, 2007.Reprints not available from the authors.
PII: S0196-0644(06)02533-9
doi:10.1016/j.annemergmed.2006.11.010
© 2007 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Patient-Tailored Acetylcysteine Administration , 06 April 2007
